A Landmark in Medicine
In a historic breakthrough for genomic medicine, baby KJ who was born with the ultra-rare and life-threatening metabolic disorder CPS1 deficiency, has become the first patient worldwide to receive a bespoke CRISPR base-editing therapy tailored to his unique genetic mutation. The treatment, developed by researchers at Children’s Hospital of Philadelphia (CHOP) in collaboration with Penn Medicine and other partners, offers a powerful example of real-world “N-of-1” gene therapy.
CPS1 deficiency is a urea-cycle disorder that prevents the liver from converting ammonia, produced during normal protein breakdown into urea for safe excretion. In affected newborns, ammonia builds to toxic levels, often causing irreversible brain damage or death. About 50 % of infants with the most severe neonatal-onset form die early in life. Affected survivors typically face profound neurological impairment with liver transplantation the only curative option so far.
KJ was diagnosed within days of birth following metabolic crises. Genetic sequencing confirmed a pathogenic CPS1 variant. With conventional care offering limited prospects, and the infant being too young for transplantation, which urged clinicians to embark on a journey to uncover an alternative solution.
From Diagnosis to Therapy in Months
Remarkably, within just six months of diagnosis, the research team designed, tested, manufactured, and gained regulatory clearance for a CRISPR base-editing therapy specific to KJ’s mutation.
The therapeutic payload was packaged into lipid nanoparticles (LNPs) to facilitate delivery to the liver. On the 25th of February 2025, when KJ was around seven months old, he received the first infusion. Followed by additional doses in March and April.
Promising Early Results
According to clinical reports, KJ tolerated all doses without serious adverse events. In the seven weeks following the initial infusion, he was able to tolerate increased dietary protein and had his nitrogen-scavenger medication dose halved. These metabolic improvements persisted even during viral illnesses, episodes that previously might have triggered dangerous ammonia spikes.
By mid-2025, KJ had been discharged from hospital and was “thriving,” according to his care team. Parents and clinicians described him meeting developmental milestones previously thought unlikely in such severe cases.
What This Means for Rare Disease Treatment
Until now, gene therapies typically targeted conditions shared by many patients, enabling economies of scale. However, most genetic disorders are rare or ultra-rare, often involving unique “private” mutations. KJ’s case demonstrates that with modern base-editing technology, lipid-nanoparticle delivery, and rapid development, truly personalised, single-patient therapies are feasible.
Researchers involved in the case now speak of this treatment as a “blueprint”, hopes are high that similar bespoke therapies could be tailored rapidly for other rare metabolic or genetic diseases.
Cautious Optimism — and the Road Ahead
While results so far are undeniably encouraging, experts emphasise that long-term follow-up remains essential to monitor for durability of gene correction, safety, and neurodevelopmental outcomes. The ethical, regulatory and manufacturing challenges of scaling personalised therapies remain substantial.
Nevertheless, KJ’s story signals a paradigm shift: from “one-size-fits-many” to “one-size-fits-one.” For patients with rare and otherwise fatal genetic disorders, bespoke CRISPR therapy may now offer a real lifeline.
Reference
